1887
  1. Home
  2. Eurosurveillance
  3. Volume 26, Issue 35, 02/Sep/2021
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

Some variants of SARS-CoV-2 are associated with increased transmissibility, increased disease severity or decreased vaccine effectiveness (VE). In this population-based cohort study (n = 4,204,859), the Delta variant was identified in 5,430 (0.13%) individuals, of whom 84 were admitted to hospital. VE against laboratory confirmed infection with the Delta variant was 22.4% among partly vaccinated (95% confidence interval (CI): 17.0−27.4) and 64.6% (95% CI: 60.6−68.2) among fully vaccinated individuals, compared with 54.5% (95% CI: 50.4−58.3) and 84.4% (95%CI: 81.8−86.5) against the Alpha variant.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.35.2100793
2021-09-02
2024-11-23
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2021.26.35.2100793
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/35/eurosurv-26-35-1.html?itemId=/content/10.2807/1560-7917.ES.2021.26.35.2100793&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC). SARS-CoV-2 variants of concern as of 15 July 2021. Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/en/covid-19/variants-concern
  2. European Centre for Disease Prevention and Control (ECDC). Threat assessment brief: implications for the EU/EEA on the spread of the SARS-CoV-2 Delta (B.1.617.2) variant of concern. Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/en/publications-data/threat-assessment-emergence-and-impact-sars-cov-2-delta-variant
  3. World Health Organization (WHO). Weekly epidemiological update on COVID-19 - 20 July 2021. Geneva: WHO; 2021. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---20-july-2021
  4. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585-94.  https://doi.org/10.1056/NEJMoa2108891  PMID: 34289274 
  5. Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461-2.  https://doi.org/10.1016/S0140-6736(21)01358-1  PMID: 34139198 
  6. Norwegian Institute of Public Health (NIPH). Ukerapporter om koronavirus og covid-19. [Weekly reports on coronavirus and COVID-19]. Oslo: NIPH; 2021. Norwegian. Available from: https://www.fhi.no/en/publ/2020/weekly-reports-for-coronavirus-og-covid-19/
  7. Norwegian Institute of Public Health (NIPH). Emergency preparedness register for COVID-19 (Beredt C19). Oslo: NIPH; 2021. Available from: https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19
  8. Norwegian Institute of Public Health (NIPH). Who will get the coronavirus vaccine? Oslo: NIPH; 2020. Available from: https://www.fhi.no/en/id/vaccines/coronavirus-immunisation-programme/who-will-get-coronavirus-vaccine-first
  9. Veneti L, Seppälä E, Larsdatter Storm M, Valcarcel Salamanca B, Alnes Buanes E, Aasand N, et al. Increased risk of hospitalisation and intensive care admission associated with infection with SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 – May 2021. SSRN. 2021.  https://doi.org/http://dx.doi.org/10.2139/ssrn.3866560 
  10. Norwegian Institute of Public Health (NIPH). Coronavirus vaccine - information for healthcare professionals. Oslo: NIPH; 2020. Available from: https://www.fhi.no/nettpub/vaksinasjonsveilederen-for-helsepersonell/vaksiner-mot-de-enkelte-sykdommene/koronavaksine/#comirnaty-koronavaksine-biontech-ogpfizer
  11. Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. medRxiv. 2021:2021.06.28.21259420.  https://doi.org/10.1101/2021.06.28.21259420 
  12. Lind A, Barlinn R, Landaas ET, Andresen LL, Jakobsen K, Fladeby C, et al. Rapid SARS-CoV-2 variant monitoring using PCR confirmed by whole genome sequencing in a high-volume diagnostic laboratory. J Clin Virol. 2021;141:104906.  https://doi.org/10.1016/j.jcv.2021.104906  PMID: 34273860 
  13. Starrfelt J, Danielsen AS, Kacelnik O, Børseth AW, Seppälä E, Meijerink H. High vaccine effectiveness against COVID-19 infection and severe disease among residents and staff of long-term care facilities in Norway, November – June 2021. medRxiv. 2021:2021.08.08.21261357.  https://doi.org/10.1101/2021.08.08.21261357 
  14. Rosenberg ES, Holtgrave DR, Dorabawila V, Conroy MB, Greene D, Lutterloh E, et al. New COVID-19 cases and hospitalizations among adults, by vaccination status—New York, May 3–July 25, 2021. MMWR Morb Mortal Wkly Rep. 2021.  https://doi.org/http://dx.doi.org/10.15585/mmwr.mm7034e1 
Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Elina+Sepp%C3%A4l%C3%A4&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Seppälä Elina</a>, <a href="/search?value1=Lamprini+Veneti&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Veneti Lamprini</a>, <a href="/search?value1=Jostein+Starrfelt&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Starrfelt Jostein</a>, <a href="/search?value1=Anders+Skyrud+Danielsen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Danielsen Anders Skyrud</a>, <a href="/search?value1=Karoline+Bragstad&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bragstad Karoline</a>, <a href="/search?value1=Olav+Hungnes&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hungnes Olav</a>, <a href="/search?value1=Arne+Michael+Taxt&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Taxt Arne Michael</a>, <a href="/search?value1=Sara+Viksmoen+Watle&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Watle Sara Viksmoen</a>, <a href="/search?value1=Hinta+Meijerink&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Meijerink Hinta</a></span>. Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021. <a href="/content/ecdc">Euro Surveill.</a> 2021;26(35):pii=2100793. <a href="https://doi.org/10.2807/1560-7917.ES.2021.26.35.2100793" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2021.26.35.2100793</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 11 Aug 2021;&nbsp;&nbsp; <span class="generated">Accepted</span>: 02 Sept 2021 </span> </p>
/content/10.2807/1560-7917.ES.2021.26.35.2100793
/content/10.2807/1560-7917.ES.2021.26.35.2100793
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error